SN-38-d3
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


SN-38-d3
Description:
SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].Product Name Alternative:
NK012-d3UNSPSC:
12352005Hazard Statement:
H301Target:
ADC Payload; Autophagy; TopoisomeraseType:
Isotope-Labeled CompoundsRelated Pathways:
Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/DNA DamageField of Research:
CancerPurity:
98.79Solubility:
DMSO : 25mg/mL (ultrasonic)Smiles:
[2H]C([2H])([2H])CC1=C2C(C(N3C2)=CC([C@](O)(C(OC4)=O)CC)=C4C3=O)=NC5=CC=C(O)C=C51Molecular Formula:
C22H17D3N2O5Molecular Weight:
395.42Precautions:
H301References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51 (16) :4187-4191.|[3]Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19 (6) :1493-8.|[4]Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56.Shipping Conditions:
Blue IceStorage Conditions:
-20°C, 3 years (Powder)Scientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development ReportedCAS Number:
[718612-49-8]
